



## Clinical trial results:

**Prospective, randomised, placebo controlled, double blind monocenter trial for the prophylactic treatment of diarrhoea with rifaximin for travellers to South- and Southeast-Asia**

### Summary

EudraCT number	2007-003986-42
Trial protocol	DE
Global end of trial date	21 September 2012

### Results information

Result version number	v1 (current)
This version publication date	03 September 2022
First version publication date	03 September 2022
Summary attachment (see zip file)	Publication (PIIS1473309913702214.pdf)

### Trial information

#### Trial identification

Sponsor protocol code	Rifa1
-----------------------	-------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00979056
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Universitätsklinikum Tübingen
Sponsor organisation address	Geissweg 3, Tübingen, Germany,
Public contact	Dr. Diane Egger-Adam, Universitätsklinikum Tübingen, Institute of Tropical Medicine, Travel Medicine & Human Parasitology, diane.egger-adam@uni-tuebingen.de
Scientific contact	Dr. Diane Egger-Adam, Universitätsklinikum Tübingen, Institute of Tropical Medicine, Travel Medicine & Human Parasitology, diane.egger-adam@uni-tuebingen.de

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	24 April 2013
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	21 September 2012
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

Main objective of the trial:

Efficacy of the prophylactic treatment with rifaximin to prevent travellers diarrhoea

Protection of trial subjects:

Study subject were trained on how to self-treat a travellers diarrhoea, if occurring. e

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 November 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Germany: 258
Worldwide total number of subjects	258
EEA total number of subjects	258

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	258
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Individuals consulting the University of Tübingen travel clinic for pre-travel advice, who planned to travel to one or more countries in south or southeast Asia for 6–28 days, and who had a predictably high risk of travellers' diarrhoea at the time of recruitment,<sup>1</sup> were invited to participate

### Pre-assignment

Screening details:

6139 subjects were screened, 1198 received the trial information and 258 were enrolled.

### Period 1

Period 1 title	Recruitment
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Verum

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Rifaximin
Investigational medicinal product code	
Other name	Xifaxan, Normix, ATC code A07AA11, Chemical Abstracts Service (CAS) 80621814
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

200 mg every 12-18h (400 mg per day)

<b>Arm title</b>	Placebo
------------------	---------

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	placebo tablets (Catalent Pharma Solutions, Schorndorf, Germany)
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

1 tablet every 12-18h (2 tablets per day)

Number of subjects in period 1	Verum	Placebo
Started	129	129
Completed	129	129

## Period 2

Period 2 title	Analysis Set
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Verum
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Rifaximin
Investigational medicinal product code	
Other name	Xifaxan, Normix, ATC code A07AA11, Chemical Abstracts Service (CAS) 80621814
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

200 mg every 12-18h (400 mg per day)

<b>Arm title</b>	Placebo
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Placeo
Investigational medicinal product code	
Other name	placebo tablets (Catalent Pharma Solutions, Schorndorf, Germany)
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

1 tablet every 12-18h (2 tables per day)

<b>Number of subjects in period 2</b>	Verum	Placebo
Started	129	129
Completed	122	117
Not completed	7	12
Lost to follow-up	7	12

## Baseline characteristics

### Reporting groups

Reporting group title	Verum
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

Reporting group values	Verum	Placebo	Total
Number of subjects	129	129	258
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	129	129	258
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous Units: years			
median	29	28	
full range (min-max)	24 to 37	26 to 36	-
Gender categorical Units: Subjects			
Female	66	65	131
Male	63	64	127
Days of travel Units: day			
median	22	21	
full range (min-max)	16 to 26	17 to 26	-

## End points

### End points reporting groups

Reporting group title	Verum
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	
Reporting group title	Verum
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

### Primary: primary endpoint

End point title	primary endpoint
End point description: Efficacy of the prevention of travellers diarrhea with rifaximin by measurement of frequency and consistence of the stool. Diarrhea will be defined as passage of >2 unformed stools/24 hr plus one or more signs or symptoms of enteric infection.	
End point type	Primary
End point timeframe: From the first day of the travel (travel period between 6 and 28 days) to 1 week after the subject's return to Germany	

End point values	Verum	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	122	117		
Units: units	30	48		

### Statistical analyses

Statistical analysis title	Analysis
Comparison groups	Verum v Placebo
Number of subjects included in analysis	239
Analysis specification	Pre-specified
Analysis type	superiority
P-value	≤ 0.5
Method	Logrank
Parameter estimate	Cox proportional hazard
Confidence interval	
level	95 %
sides	1-sided
Variability estimate	Standard deviation

---

**Secondary: 1. Secondary endpoint**

---

End point title	1. Secondary endpoint
-----------------	-----------------------

End point description:

Documentation of adverse effects and tolerance of prophylaxis with rifaximin.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first day of the travel (travel period between 6 and 28 days) to 1 week after the subject's return to Germany

---

End point values	Verum	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	122	117		
Units: incidences	112	112		

---

**Statistical analyses**

---

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From the first day of the travel (travel period between 6 and 28 days) to 1 week after the subject's return to Germany

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18
--------------------	----

### Reporting groups

Reporting group title	Verum
-----------------------	-------

Reporting group description: -

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Serious adverse events	Verum	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 122 (0.82%)	0 / 117 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Gastrointestinal disorders			
right lower quadrant abdominal pain	Additional description: Grad 3 right lower quadrant abdominal pain 72h after serum intake		
subjects affected / exposed	1 / 122 (0.82%)	0 / 117 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Verum	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	112 / 122 (91.80%)	112 / 117 (95.73%)	
Nervous system disorders			
Headache			
subjects affected / exposed	53 / 122 (43.44%)	45 / 117 (38.46%)	
occurrences (all)	96	83	
Gastrointestinal disorders			
Abdominal pain			

subjects affected / exposed	66 / 122 (54.10%)	77 / 117 (65.81%)	
occurrences (all)	136	152	
Flatulence			
subjects affected / exposed	57 / 122 (46.72%)	55 / 117 (47.01%)	
occurrences (all)	121	100	
Nausea			
subjects affected / exposed	42 / 122 (34.43%)	57 / 117 (48.72%)	
occurrences (all)	62	85	
Vomiting			
subjects affected / exposed	19 / 122 (15.57%)	19 / 117 (16.24%)	
occurrences (all)	20	23	
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	26 / 122 (21.31%)	12 / 117 (10.26%)	
occurrences (all)	38	17	
Metabolism and nutrition disorders			
Fever	Additional description: Fever more or equal to 37.8°C		
subjects affected / exposed	18 / 122 (14.75%)	23 / 117 (19.66%)	
occurrences (all)	24	34	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/24012319>